Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Common Equity (2018 - 2025)

Neurogene's Common Equity history spans 6 years, with the latest figure at $264.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 14.66% year-over-year to $264.9 million; the TTM value through Dec 2025 reached $264.9 million, down 14.66%, while the annual FY2025 figure was $264.9 million, 14.66% down from the prior year.
  • Common Equity reached $264.9 million in Q4 2025 per NGNE's latest filing, roughly flat from $265.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $310.4 million in Q4 2024 to a low of -$183.2 million in Q3 2023.
  • Average Common Equity over 3 years is $128.8 million, with a median of $178.4 million recorded in 2023.
  • Peak YoY movement for Common Equity: surged 208.36% in 2024, then decreased 14.66% in 2025.
  • A 3-year view of Common Equity shows it stood at $186.0 million in 2023, then skyrocketed by 66.85% to $310.4 million in 2024, then fell by 14.66% to $264.9 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Common Equity are $264.9 million (Q4 2025), $265.5 million (Q3 2025), and $273.3 million (Q2 2025).